𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Session 14: Plaques and amyloids


Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
513 KB
Volume
50
Category
Article
ISSN
0022-2135

No coin nor oath required. For personal study only.

✦ Synopsis


Conclusion:

Confirmation of the specificity of [ 18 F]-FEDAA1106 for PBR expressed in activated macrophages in the atherosclerotic plaque is a necessary prequel to evaluating the efficacy of this PET radioligand in a rabbit model of atheroma. The successful conclusion of these experiments will generate a powerful clinical tool for determining atheroma instability in man.


πŸ“œ SIMILAR VOLUMES


Session 7: Amyloid plaque
πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 191 KB
Session 14: Basic Radiochemistry II-Misc
πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 601 KB

## Introduction. Shell crosslinked nanoparticles (SCKs) are amphiphilic core-shell nanoparticles inspired from biological constructs (1-2). They are prepared by the self-assembly and subsequent crosslinking of block copolymer micelles and can be optimized for guest packaging. The easily controlled

CR1 is associated with amyloid plaque bu
✍ Lori B. Chibnik; Joshua M. Shulman; Sue E. Leurgans; Julie A. Schneider; Robert πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 180 KB

## Abstract ## Objective Recently, genome‐wide association studies have identified 3 new susceptibility loci for Alzheimer's disease (AD), __CLU, CR1__, and __PICALM__. We leveraged available neuropsychological and autopsy data from 2 cohort studies to investigate whether these loci are associated

Design, structural, and immuno-analytica
✍ Marilena Manea; Michael Przybylski; Ferenc Hudecz; GΓ‘bor MezΓΆ πŸ“‚ Article πŸ“… 2008 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 512 KB

## Abstract Immunotherapeutic approaches are investigated for treatment of neurodegenerative diseases of the Alzheimer's dementia (AD) type. The identification of a β‐amyloid‐plaque specific epitope, AΞ²(4‐10) (^4^FRHDSGY^10^), recognized by therapeutically active antibodies from transgenic AD mice